Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- GastroEsophageal Cancer
- Head and Neck Cancer
- Hepatocellular Cancer
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Thyroid Cancer
- Urothelial Carcinoma (UC)
- Cholangiocarcinoma
- Mesothelioma
- Gallbladder Cancer
- Ovarian Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Sarah Cannon Research Institute · Denver, CO
Florida · 1
- Sylvester Comprehensive Cancer Center - University of Miami Health System · Miami, FL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- NEXT Oncology · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.